Publications by authors named "C Giofre"
Psoriasis is a chronic immune-mediated disease that can be challenging to treat, especially in patients with severe disease or high body weight. Tildrakizumab is a monoclonal antibody which inhibits IL-23, approved for moderate-to-severe psoriasis with a standard 100 mg dose. A 200 mg dose may provide greater efficacy for patients over 90 kg or with high disease burden.
View Article and Find Full Text PDFIntroduction: Tildrakizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin 23 (IL-23), has shown promise in the management of moderate-to-severe plaque psoriasis, offering potential improvements in clinical outcomes and quality of life.
Objectives: The study aimed to identify patient characteristics that indicate the initiation of a 200 mg dosage of tildrakizumab in a real-world setting, focusing on factors that enhance treatment effectiveness and safety.
Methods: This prospective study included 54 adult patients with moderate-to-severe plaque psoriasis treated with tildrakizumab 200 mg from March 2023 to March 2024 across 13 Italian Dermatology Units.
Eczematous reactions in patients with plaque psoriasis receiving biological therapy: an observational study.
Eur Rev Med Pharmacol Sci
September 2024
Article Synopsis
- The study investigated eczematous reactions in psoriasis patients treated with biologic agents, specifically TNF-α and IL-17A inhibitors, highlighting the lack of complete understanding of these side effects.
- Conducted in Italy with 54 patients, the research noted that many had personal or family histories of atopy, and eczema could appear within days to years after starting treatment, with a notable number of cases linked to anti-IL-17 therapies.
- The findings suggest switching to IL-23 inhibitors can lead to rapid eczema remission without relapse, indicating such treatments may be preferable for patients with a history of atopic dermatitis.
Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully humanized monoclonal antibody, was the first anti-interleukin (IL)-17 biologic approved for treating psoriasis.
View Article and Find Full Text PDFPsoriasis is a chronic inflammatory skin condition that affects millions of individuals worldwide, impacting their physical and emotional well-being. The management of psoriasis requires effective communication and a strong physician-patient relationship. We aim to develop a novel algorithm to enhance patient well-being and care in moderate-to-severe psoriasis, considering the time constraints that dermatologists have in public hospitals.
View Article and Find Full Text PDF